《瑞信窩輪》藥股偏軟新地反彈,留意石藥牛68988、新地購21972
醫藥股石藥集團(1093)季績公布前,周一窄幅整固,低位暫守20元關口。向上留意重上一個月高位21.65元的機會, 20元關口或繼續尋求支持。看好可考慮石藥購12746,行使價22.88元,20年7月到期。或石藥牛68988,收回價19.68元,行使價18.98元,20年6月到期。相反看淡可留意石藥沽12763,行使價17.78元,20年5月到期。或石藥熊68990,收回價22.78元,行使價23.48元,20年4月到期。
中國生物製藥(1177)周一逆市跌逾1%,低位暫守11元。看好可考慮中藥購23888,行使價12.68元,20年2月到期。或中藥牛68997,收回價10.38元,行使價9.98元,20年7月到期。相反看淡可考慮中藥沽26729,行使價10.88元,20年3月到期。
吉利汽車(0175)周一升逾2%,重上15元關口並曾高見15.2元水平。看好可留意吉利購12739,行使價19.12元,20年7月到期。或50兌1吉利牛64358,收回價14.38元,行使價13.88元,20年10月到期。相反看淡可留意吉利沽12676,行使價14.38元,20年5月到期。或50兌1吉利熊59534,收回價16.08元,行使價16.58元,20年1月到期。
早前受示威活動拖累而捱沽的新地(0016),周一出現反彈,高位曾升逾3%至111元以上。看好可留意新地購21972,行使價124.88元,20年2月到期。或新地牛52599,收回價102.88元,行使價101.38元,20年4月到期。相反看淡則可留意新地沽23804,行使價109.78元,20年2月到期。
港鐵(0066)周一靠穩,徘徊在43元附近。看好可留意港鐵購23412,行使價47.88元,20年2月到期。相反看淡則可留意港鐵沽29064,行使價39.34元,20年4月到期。
(本結構性產品並無抵押品)
《瑞信香港認股證及牛熊證銷售主管何啟聰》
免責聲明:筆者為瑞士信貸(香港)有限公司的代表 ,並身為證監會持牌人,並無持有相關上市公司的任何財務權益。本文內容僅供參考,並不構成要約、建議或促使任何人士提呈買賣或認購任何證券。結構性產品價格可急升或急跌,投資者或會蒙受全盤損失。本產品並無抵押品。如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。牛熊證備強制贖回機制而可能被提早終止,屆時(i)N類牛熊證投資者將不獲發任何金額;而(ii)R類牛熊證之剩餘價值可能為零。有關恆生指數或恆生中國企業指數的免責聲明,請參閱上市文件。過往表現並不反映將來表現。投資前,投資者應瞭解風險,並諮詢專業顧問及查閱有關上市文件。瑞信之聯屬公司為結構性產品之流通量提供者,亦可能是唯一報價者。本文任何內容概不構成投資、法律、會計或稅務意見、並無聲明任何投資或策略適合或符合閣下的個別情況。結構性產品交投量並不是結構性產品表現的指標,投資者不應僅依賴交投量歷史高位數據以釐定結構性產品日後的表現。~重要聲明:
以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.